NasdaqGS - Nasdaq Real Time Price • USD
Agios Pharmaceuticals, Inc. (AGIO)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 8 | 9 |
| Avg. Estimate | -1.64 | -1.66 | -5.8 | -5.89 |
| Low Estimate | -1.78 | -1.82 | -7.13 | -8.8 |
| High Estimate | -1.48 | -1.46 | -3.03 | -3.14 |
| Year Ago EPS | -1.47 | -1.51 | -6.33 | -5.8 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 8 | 9 |
| Avg. Estimate | 8.69M | 9.51M | 42.65M | 113.7M |
| Low Estimate | 7.1M | 7.5M | 31M | 65.4M |
| High Estimate | 12.92M | 14.91M | 62.66M | 273M |
| Year Ago Sales | 5.61M | 6.46M | 26.82M | 42.65M |
| Sales Growth (year/est) | 54.90% | 47.20% | 59.00% | 166.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.7 | -1.56 | -1.7 | -1.65 |
| EPS Actual | -1.47 | -1.51 | -1.64 | -1.72 |
| Difference | 0.23 | 0.05 | 0.06 | -0.07 |
| Surprise % | 13.50% | 3.20% | 3.50% | -4.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.64 | -1.66 | -5.8 | -5.89 |
| 7 Days Ago | -1.64 | -1.66 | -5.8 | -5.89 |
| 30 Days Ago | -1.64 | -1.66 | -5.8 | -5.87 |
| 60 Days Ago | -1.63 | -1.66 | -5.45 | -5.86 |
| 90 Days Ago | -1.56 | -1.61 | -5.01 | -6.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AGIO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -11.60% | -- | -- | 1.60% |
| Next Qtr. | -9.90% | -- | -- | 10.50% |
| Current Year | 8.40% | -- | -- | 5.20% |
| Next Year | -1.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 39.00% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 4/9/2024 |
| Maintains | JP Morgan: Neutral to Neutral | 2/23/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 2/16/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 11/3/2023 |
| Maintains | JP Morgan: Neutral to Neutral | 8/7/2023 |
| Maintains | RBC Capital: Outperform to Outperform | 6/27/2023 |
Related Tickers
PTCT PTC Therapeutics, Inc.
25.32
+2.55%
BPMC Blueprint Medicines Corporation
86.85
-2.31%
ENTA Enanta Pharmaceuticals, Inc.
13.32
+0.68%
ANAB AnaptysBio, Inc.
19.87
+0.20%
AVTE Aerovate Therapeutics, Inc.
22.05
+2.08%
ALNY Alnylam Pharmaceuticals, Inc.
144.41
-0.52%
KURA Kura Oncology, Inc.
17.53
-0.85%
YMAB Y-mAbs Therapeutics, Inc.
15.13
+0.87%
ABVX ABIVAX Société Anonyme
15.31
+2.48%
MLYS Mineralys Therapeutics, Inc.
11.29
+5.02%